285 related articles for article (PubMed ID: 22473253)
1. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
2. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal gammopathy of unknown significance in kidney transplanted patients: novel insights into long-term outcomes.
Meuleman MS; Mouyabi S; Gueguen J; Vicca S; Divard G; Aubert O; Bienaimé F; Arnulf B; Anglicheau D; Bridoux F; Cohen C
Nephrol Dial Transplant; 2023 Dec; 39(1):64-73. PubMed ID: 37403344
[TBL] [Abstract][Full Text] [Related]
4. What is the significance of monoclonal gammopathy of undetermined significance?
Atkin C; Richter A; Sapey E
Clin Med (Lond); 2018 Oct; 18(5):391-396. PubMed ID: 30287433
[TBL] [Abstract][Full Text] [Related]
5. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
[TBL] [Abstract][Full Text] [Related]
6. Multimorbidity in patients with monoclonal gammopathy of undetermined significance.
Epstein MM; Zhou Y; Castaneda-Avila MA; Cohen HJ
Int J Cancer; 2023 Jun; 152(12):2485-2492. PubMed ID: 36799553
[TBL] [Abstract][Full Text] [Related]
7. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.
Goyal G; Rajkumar SV; Lacy MQ; Gertz MA; Buadi FK; Dispenzieri A; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kourelis TV; Warsame R; Kyle RA; Kumar SK
Leukemia; 2019 May; 33(5):1273-1277. PubMed ID: 30787429
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D and monoclonal gammopathy of undetermined significance (MGUS) among U.S. Black women.
Ruiz Lopez JN; McNeil GE; Zirpoli G; Palmer JR; Kataria Y; Bertrand KA
Cancer Causes Control; 2024 Feb; 35(2):277-279. PubMed ID: 37707565
[TBL] [Abstract][Full Text] [Related]
9. Post-Transplant Monoclonal Gammopathy of Renal Significance: A Case Report.
Movilla Echeverri C; Montilla Cosano G; Rivera Garrido C; Suñer Poblet M; Suarez Benjumea A
Transplant Proc; 2023 Dec; 55(10):2301-2303. PubMed ID: 38030424
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Gammopathy and Its Association with Progression to Kidney Failure and Mortality in Patients with CKD.
Sy-Go JPT; Moubarak S; Vaughan LE; Klomjit N; Viehman JK; Fervenza FC; Zand L
Clin J Am Soc Nephrol; 2024 Mar; 19(3):319-328. PubMed ID: 37948069
[TBL] [Abstract][Full Text] [Related]
11. The Hematologic Definition of Monoclonal Gammopathy of Undetermined Significance in Relation to Paraproteinemic Keratopathy (An American Ophthalmological Society Thesis).
Lisch W; Wasielica-Poslednik J; Kivelä T; Schlötzer-Schrehardt U; Rohrbach JM; Sekundo W; Pleyer U; Lisch C; Desuki A; Rossmann H; Weiss JS
Trans Am Ophthalmol Soc; 2016 Aug; 114():T7. PubMed ID: 28050052
[TBL] [Abstract][Full Text] [Related]
12. Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma.
Greenberg AJ; Cousin M; Kumar S; Ketterling RP; Knudson RA; Larson D; Colby C; Scott C; Vachon CM; Vincent Rajkumar S
Eur J Haematol; 2013 Sep; 91(3):193-195. PubMed ID: 23647020
[TBL] [Abstract][Full Text] [Related]
13. Regression of Intermediate-High Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) With Long-term Use of Curcumin: A Case Report.
Golombick T; Ramakrishna R; Manoharan A
Integr Cancer Ther; 2024; 23():15347354241242099. PubMed ID: 38529782
[TBL] [Abstract][Full Text] [Related]
14. Mortality in the US Populations With Monoclonal Gammopathy of Undetermined Significance.
Ji M; Huber JH; Schoen MW; Sanfilippo KM; Colditz GA; Wang SY; Chang SH
JAMA Oncol; 2023 Sep; 9(9):1293-1295. PubMed ID: 37498610
[TBL] [Abstract][Full Text] [Related]
15. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.
Landgren O; Kyle RA; Rajkumar SV
Clin Cancer Res; 2011 Mar; 17(6):1243-52. PubMed ID: 21411440
[TBL] [Abstract][Full Text] [Related]
16. Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma.
Hermouet S; Bigot-Corbel E; Harb J
Front Immunol; 2023; 14():1253363. PubMed ID: 38022528
[TBL] [Abstract][Full Text] [Related]
17. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A; Ferrari F; Freeman SS; Redd R; El-Khoury H; Perry J; Patel V; Kaur P; Barr H; Lee DJ; Lightbody E; Downey K; Argyelan D; Theodorakakou F; Fotiou D; Liacos CI; Kanellias N; Chavda SJ; Ainley L; Sandecká V; Pospíšilová L; Minarik J; Jungova A; Radocha J; Spicka I; Nadeem O; Yong K; Hájek R; Kastritis E; Marinac CR; Dimopoulos MA; Get G; Trippa L; Ghobrial IM
Lancet Haematol; 2023 Mar; 10(3):e203-e212. PubMed ID: 36858677
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.
Rodríguez-García A; Linares M; Morales ML; Allain-Maillet S; Mennesson N; Sanchez R; Alonso R; Leivas A; Pérez-Rivilla A; Bigot-Corbel E; Hermouet S; Martínez-López J
Front Immunol; 2021; 12():797209. PubMed ID: 35087522
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal gammopathy of undetermined significance (MGUS) manifestation in CNS: a regular or chance occurrence?
Prakhova L; Lebedev V; Ilves A; Nazinkina Y
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33762271
[TBL] [Abstract][Full Text] [Related]
20. The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans.
Liu LW; Wang M; Grandhi N; Schroeder MA; Thomas T; Vargo K; Gao F; Sanfilippo KM; Chang SH
J Hematol Oncol; 2024 Jan; 17(1):3. PubMed ID: 38191467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
